Skip to content
OpenCapital
Get started

Design Therapeutics, Inc. DSGN Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
——

Other financials

Income statement

See full
Revenue-—
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$839.42M+295%
Enterprise value$829.39M+313%

Profitability

See full
Operating margin-3,685.8%—
Net margin-3,663.7%—

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0×0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Design Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
Design Therapeutics, Inc. (DSGN) reported proceeds from sale and maturity of available for sale securities of $45M in Q1 2026.
How has Design Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?
Design Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities decreased by 52.4% year-over-year, from $94.49M to $45M.
What is the long-term trend for Design Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities has grown at a 74.3% compound annual growth rate (CAGR), from $34.16M to $314.89M.